Trial for gout drug meets primary endpoint, raises safety

http://ift.tt/eA8V8J Febuxostat, a gout drug that has been in use for nearly a decade, was found to significantly increase the risk of death, even though it did not raise the risk of the trial's primary endpoint, a combined rate of fatal and nonfatal adverse cardiovascular events, according to new research.

from http://ift.tt/2Fxw4sV
via IFTTT